{
    "organizations": [],
    "uuid": "fb4cebfd6af212cd01a12c339d9a9e1742d5e997",
    "author": "",
    "url": "https://www.reuters.com/article/brief-genocea-files-ind-for-neoantigen-c/brief-genocea-files-ind-for-neoantigen-cancer-vaccine-candidate-gen-009-idUSFWN1S70ZL",
    "ord_in_thread": 0,
    "title": "BRIEF-Genocea Files IND For Neoantigen Cancer Vaccine Candidate Gen-009",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 30, 2018 / 1:40 PM / Updated 10 minutes ago BRIEF-Genocea Files IND For Neoantigen Cancer Vaccine Candidate Gen-009 Reuters Staff 1 Min Read\nApril 30 (Reuters) - Genocea Biosciences Inc:\n* GENOCEA - FILES IND FOR NEOANTIGEN CANCER VACCINE CANDIDATE GEN-009, PLANS TO INITIATE PHASE 1/2A CLINICAL PROGRAM LATER THIS YEAR\n* GENOCEA - TOP-LINE IMMUNE RESPONSE DATA FROM STUDY EXPECTED IN THE FIRST HALF OF 2019 Source text: ( bit.ly/2r7ztW4 ) Further company coverage:",
    "published": "2018-04-30T16:38:00.000+03:00",
    "crawled": "2018-04-30T17:00:47.011+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "file",
        "ind",
        "neoantigen",
        "cancer",
        "vaccine",
        "candidate",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "genocea",
        "bioscience",
        "inc",
        "genocea",
        "file",
        "ind",
        "neoantigen",
        "cancer",
        "vaccine",
        "candidate",
        "plan",
        "initiate",
        "phase",
        "clinical",
        "program",
        "later",
        "year",
        "genocea",
        "immune",
        "response",
        "data",
        "study",
        "expected",
        "first",
        "half",
        "source",
        "text",
        "company",
        "coverage"
    ]
}